|
HU219131B
(hu)
|
1991-10-18 |
2001-02-28 |
Monsanto Co. |
Módszer és fungicid készítmény növények torsgombabetegségének gátlására és a hatóanyagok
|
|
SE9703407D0
(sv)
*
|
1997-09-19 |
1997-09-19 |
Astra Ab |
New use
|
|
SE9802073D0
(sv)
|
1998-06-11 |
1998-06-11 |
Astra Ab |
New use
|
|
GB9825554D0
(en)
*
|
1998-11-20 |
1999-01-13 |
Smithkline Beecham Spa |
Novel Compounds
|
|
US7037922B1
(en)
*
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
AU4038600A
(en)
|
1999-03-29 |
2000-10-16 |
Neurogen Corporation |
4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
|
|
WO2000064877A1
(en)
*
|
1999-04-26 |
2000-11-02 |
Neurogen Corporation |
2-aminoquinolinecarboxamides: neurokinin receptor ligands
|
|
JP2004525183A
(ja)
*
|
2001-04-11 |
2004-08-19 |
グラクソスミスクライン・ソシエタ・ペル・アチオニ |
Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしてのキノリン−４−カルボキサミド誘導体
|
|
WO2002089802A2
(en)
*
|
2001-05-08 |
2002-11-14 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
SI2246360T1
(sl)
|
2003-01-28 |
2012-10-30 |
Ironwood Pharmaceuticals Inc |
Sestavki za zdravljenje gastrointestinalnih motenj
|
|
GB0303086D0
(en)
*
|
2003-02-11 |
2003-03-19 |
Merck Sharp & Dohme |
New compounds
|
|
GB0419192D0
(en)
|
2004-08-27 |
2004-09-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2006052722A1
(en)
*
|
2004-11-09 |
2006-05-18 |
Smithkline Beecham Corporation |
Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
|
|
GB0425077D0
(en)
*
|
2004-11-12 |
2004-12-15 |
Smithkline Beecham Corp |
Novel compounds
|
|
GB0515580D0
(en)
|
2005-07-29 |
2005-09-07 |
Merck Sharp & Dohme |
Therapeutic compounds
|
|
WO2007018466A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Astrazeneca Ab |
Alkylpyridyl quinolines as nk3 receptor modulators
|
|
AR057130A1
(es)
|
2005-09-21 |
2007-11-14 |
Astrazeneca Ab |
Quinolinas de alquilsulfoxido y una composicion farmaceutica
|
|
TW201018662A
(en)
*
|
2005-12-12 |
2010-05-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
ES2559319T3
(es)
|
2007-06-04 |
2016-02-11 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
KR20100087300A
(ko)
*
|
2007-09-28 |
2010-08-04 |
글락소스미스클라인 엘엘씨 |
글리코겐 포스포릴라아제 억제제 화합물 및 이의 약학적 조성물
|
|
CA2701020A1
(en)
*
|
2007-09-28 |
2009-04-09 |
Glaxosmithkline Llc |
Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
|
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
JP5502106B2
(ja)
|
2008-12-31 |
2014-05-28 |
アーデリクス，インコーポレーテッド |
体液貯留または塩分過負荷と関連する障害および消化管障害の治療におけるｎｈｅ媒介性アンチポートを阻害するための組成物および方法
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
WO2014029983A1
(en)
|
2012-08-21 |
2014-02-27 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
EP2983667B1
(en)
|
2013-04-12 |
2019-03-20 |
Ardelyx, Inc. |
Nhe3-binding compounds and methods for inhibiting phosphate transport
|
|
US9475773B2
(en)
|
2013-04-19 |
2016-10-25 |
Astrazeneca Ab |
NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
|
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
KR20240090875A
(ko)
|
2017-01-09 |
2024-06-21 |
알데릭스, 인코포레이티드 |
위장관 장애를 치료하는 데 유용한 화합물
|
|
EP3565811A1
(en)
|
2017-01-09 |
2019-11-13 |
Ardelyx, Inc. |
Inhibitors of nhe-mediated antiport
|